Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Biocon Biologics Inc.

N OTE: This order is nonprecedential.
United States Court of Appeals
for the Federal Circuit
______________________
REGENERON PHARMACEUTICALS, INC.,
Plaintiff-Appellant
v.
MYLAN PHARMACEUTICALS INC., BIOCON
BIOLOGICS INC.,
Defendants-Cross-Appellants
AMGEN USA, INC.,
Defendant
______________________
2024-1402, 2024-1405
______________________
Appeals from the United States District Court for the
Northern District of West Virginia in No. 1:22-cv-00061-
TSK-JPM, Chief Judge Thomas S. Kleeh.
______________________
Before CHEN, L INN, and HUGHES , Circuit Judges.
P ER CURIAM .
O R D E R
Following this court’s February 22, 2024 show cause
order, the parties agree that the court lacks jurisdiction
over both the appeal and cross-appeal from the district
court’s December 27, 2023 decision resolving fewer than all
Case: 24-1402 Document: 26 Page: 1 Filed: 04/12/2024

-- 1 of 2 --

REGENERON PHARMACEUTICALS, INC. v. MYLAN
PHARMACEUTICALS INC.
2
claims at issue. Under the circumstances, we agree and
conclude that dismissal is appropriate.
Accordingly,
I T I S O RDERED T HAT :
(1) Appeal Nos. 2024-1402 and 2024-1405 are dis-
missed.
(2) Each party shall bear its own costs.
April 12, 2024
Date
F OR THE COURT
ISSUED AS A MANDATE: April 12, 2024
Case: 24-1402 Document: 26 Page: 2 Filed: 04/12/2024

-- 2 of 2 --